Privately held Zavante Therapeutics Inc. hopes an intravenous formulation of an epoxide antibiotic first approved 20 years ago might hold the answer to addressing multi-drug resistant complicated urinary tract infections (cUTI), and now has Phase III data demonstrating non-inferiority against a control regimen of existing antibiotic combination therapy.
The San Diego biotech reported on April 6 that the ZEUS trial of Zolyd (fosfomycin) showed non-inferiority against a control arm of piperacillin/tazobactam
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?